NFE2L2 and Friedreich ataxia: NRF2 activation is neuroprotective in models of neurological disorders such as Parkinson’s disease and multiple sclerosis [6,46], thus, the activation of NRF2 signaling may also be an attractive pharmacological target for neuroprotection in FRDA.